

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

Effect of intravenous somatostatin on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio-Pancreatography) in comparison with control group

Protocol summary

Study aim

Determination and comparison of PEP(post-ERCP Pancreatitis) incidence in patients receiving prophylactic intravenous bolus somatostatin plus rectal diclofenac versus placebo plus rectal diclofenac.

Design

Clinical trial with intervention and control groups, double blind, randomized, phase three. Randomization: Random block A, B. Randomization Unit: Individual. Randomization tool: random number table. The operating physician, assistant and patient will not be aware of any syringe content. Sample size: 50 patients in control group and 50 patients in intervention group.

Settings and conduct

Participants will be randomly divided into two groups of patients and controls. The operating physician, assistant, and patient will not be aware of any needle syringes (double blind). Randomly block A, B, individual randomization unit, table randomization tool. The drug syringe contains 250 micrograms of somatostatin and the placebo syringe contains distilled water. The endoscopy unit of Firoozgar Hospital will be located in Tehran.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age over 18 years ; Ability to sign consent ; Intact papillae ; No contraindication for somatostatin and diclofenac ; Having an ERCP indication ; Non-inclusion: Sphincterotomy ; Acute pancreatitis ; Basic amylase above 200 ; Allergy to somatostatin and diclofenac ;

Intervention groups

Intervention group: intravenous injection of 250 µg Somatostatin Control group: drug injection (distilled water)

Main outcome variables

Acute pancreatitis after ERCP

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191231045969N1**

Registration date: **2020-02-18, 1398/11/29**

Registration timing: **registered_while_recruiting**

Last update: **2020-02-18, 1398/11/29**

Update count: **0**

Registration date

2020-02-18, 1398/11/29

Registrant information

Name

Mehdi Nikkhah

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8214 1711

Email address

nikkhah.m@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-08-27, 1397/06/05

Expected recruitment end date

2020-03-19, 1398/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of intravenous somatostatin on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio-Pancreatography) in comparison with control group

Public title

The effect of intravenous somatostatin on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio-Pancreatography)

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria:

Age over 18 years Ability to sign consent Intact papillae
No contraindication for somatostatin and diclofenac
Having an ERCP indication

Exclusion criteria:

Sphincterotomy Acute pancreatitis Basic amylase above 200 Allergy to somatostatin and diclofenac

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator
- Outcome assessor

Sample size

Target sample size: **100**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization Method: Block A, B is random. Patients will be placed in pre-arranged charts in which A, B are listed, respectively, at the time of study, thereby prescribing for block A, the syringe containing the drug, and for block B, the syringe containing the drug. The operating physician, assistant, and patient will not be aware of any syringe content and the syringe code will be written to the file (double blind). Randomization Unit: Individual Randomization Tool: Table

Blinding (investigator's opinion)

Double blinded

Blinding description

Patients will be randomly assigned to block A and B randomly with the table randomization tool. The syringe code will be written to the file. The operating physician, assistant and patient will not be aware of any syringe content. (Double blind).

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Iran University of Medical Sciences

Street address

Iran University of Medical Sciences, next to Milad Tower, Hemat Highway, Tehran

City

Tehran

Province

Tehran

Postal code

1449614535

Approval date

2018-08-26, 1397/06/04

Ethics committee reference number

IR.IUMS.REC.1397.290

Health conditions studied

1

Description of health condition studied

Acute pancreatitis

ICD-10 code

K85

ICD-10 code description

Acute pancreatitis

Primary outcomes

1

Description

Acute pancreatitis after ERCP

Timepoint

24 hours after ERCP operation

Method of measurement

Examination and testing of lipase amylase

Secondary outcomes

empty

Intervention groups

1

Description

Control group: Intravenous (distilled water) injection, 5cc intravenous injection, a syringe (no content and only one code insert) given to physician assistant to slow it for 1 to 2 minutes simultaneously Injections for the patient. The name of the distilled water company is SUPA and its chemical compound is H2O.

Category

Placebo

2

Description

Intervention group: Intravenous injection of 250 µg somatostatin (250 µg somatostatin dissolved in 5 ml distilled water), a syringe (without mentioning content and with only one code insert) given to the physician assistant slowly Inject 1 to 2 minutes with the cannulation for the patient. The manufacturer's name is somatostatin consumable, Eumedica.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Firoozgar hospital

Full name of responsible person

Mehdi Nikkha

Street address

Firoozgar Hospital, Beh Afarin Street, Vali Asr Square

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8893 7383

Fax

+98 21 8893 7383

Email

nikkhah.m@iums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Dr Abbas Motevalian

Street address

Iran University of Medical Sciences, next to Milad Tower, Hemat Highway, Tehran

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 8670 2504

Email

amotevalian@iums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor

organization/entity?

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Mehdi Nikkhah

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Firoozgar Hospital, Beh Afarin Street, Vali Asr Square

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8893 7383

Email

Nikkhah.m@iums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Mehdi Nikkhah

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Firoozgar Hospital, Beh Afarin Street, Vali Asr Square

City

Tehran

Province

Tehran

Postal code

1593748711

Phone

+98 21 8893 7383

Email

nikkhah.m@iums.ac.ir

Phone

+98 21 8893 7383

Email

Nikkhah.m@iums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Mehdi Nikkhah

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Internal Medicine

Street address

Firoozgar Hospital, Beh Afarin Street, Vali Asr Square

City

Tehran

Province

Tehran

Postal code

1593748711

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available